PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02515-1 ↗Kurz gefasst
Leserbrief in der Zeitschrift Medical Oncology, 2024. Verfasst von Kadri Altundag. Beteiligte Einrichtung: MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey. altundag66@yahoo.com. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey. altundag66@yahoo.com.
Zitieren
APA
Altundag, K. (2024). PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer. Medical Oncology. https://doi.org/10.1007/s12032-024-02515-1
Vancouver
Altundag K. PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer. Medical Oncology. 2024. doi:10.1007/s12032-024-02515-1
BibTeX
@article{Altundag2024,
author = {Altundag, Kadri},
title = {PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02515-1}
}
EUVIMED